Plain-English translation of NCT07410117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , an experimental medication, can prevent blood clots in people with advanced solid tumors who are undergoing cancer treatment. Blood clots are a known complication that can happen to cancer patients, and this study is asking whether this new treatment can help keep them safe. Researchers will compare people who receive the medication to those who receive a placebo (an inactive treatment) to see if it actually works.
Cancer patients have a higher risk of developing dangerous blood clots, which can lead to serious complications. Currently, there are limited prevention options for this problem, so doctors are testing whether this medication could offer patients better protection.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication or a placebo, and you would take it regularly throughout the study period while you receive your cancer treatment. You would visit the study clinic for appointments to check your health, have blood tests taken, and report any side effects. The study tracks whether you develop blood clots and monitors your overall safety during treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Georgia